2025 Global biotech survey report
How ambiguity is shaping biotech ambition
What is the report about?
In 2025 ICON Biotech surveyed over 260 biotech leaders, in China and worldwide. The global survey report tracks the changes since our 2023 survey. The supplemental China report focuses on 100 biotech leaders’ experiences today, within this significant biotech region.
Download the 2025 Global survey and discover what’s next for biotech.
In 2023 ICON Biotech carried out extensive research on the experiences of biotech leaders and funders worldwide. Two years later we repeated the survey with a larger group of respondents (163) and some additional questions.
We sought commentary from Venture Capital firms to add context and regional perspectives. This report also explores how China has consolidated its position as a biotech and life sciences hub and how the rest of the world plans to respond.
What has changed in the biotech sector?
Discover what’s changed since 2023, which therapeutic areas have waned, and which modalities are on the rise. Learn how geopolitical uncertainty and competition from China are reshaping the sector with analysis of 163 biotech leaders’ responses and commentary from VC experts. Get data-driven insights and anticipate what’s next for biotech in 2026 including:
- Funding trends
- Therapeutic area activities
- Trends in modalities
- VC commentary
- EU & US responses to China’s biotech growth
- Geopolitical challenges
- The patent cliff and biosimilars
- Biotech sentiment
- Potential opportunities
- Securing the talent pipeline
Want to explore regional dynamics?
Download the 2025 China biotech sector survey today.